

Regimen Reference Order – GAST – lanreotide

Planned Course: Every 28 days until disease progression or unacceptable toxicity

Indication for Use: Neuroendocrine tumors (NET)

CVAD: Not Required

Proceed with treatment if:

❖ *Blood work not required*

SEQUENCE OF MEDICATION ADMINISTRATION

Pre-treatment Requirements

Drug	Dose	CCMB Administration Guideline
Not Applicable		

Treatment Regimen – GAST – lanreotide

Drug	Dose	CCMB Administration Guideline
lanreotide	120 mg	Deep subcutaneous injection in the superior external quadrant of the buttock alternating left and right

In the event of a hypersensitivity reaction, refer to the 'Hypersensitivity Reaction Standing Order'

REQUIRED MONITORING

Every 3 months

- CBC, urea, creatinine, electrolytes, liver function tests, as per physician order

Recommended Support Medications

Drug	Dose	CCMB Administration Guideline
Not Applicable		

DISCHARGE INSTRUCTIONS

- lanreotide must be stored in the fridge between 2 to 8 degrees Celsius

ADDITIONAL INFORMATION

- Prior to first dose of lanreotide, a test dose of octreotide immediate release (usual 50 mcg) is administered subcutaneously followed by an observation period, as per physician order
- If administered in the treatment room, patient needs to bring their own supply of prefilled syringe (Somatuline® Depot)
- lanreotide can cause cholelithiasis and increased blood sugar